Fig 1: Knockdown of PDCD10 enhances the self-renewal capacity of U87-RG cells and GSCs generated from the parental cell line U87-RG (U87-RG-GSCs), and increases the expression of stem cell markers in RG-GSCs. (A) Representative images of neurospheres derived from U87-RG cells and U87-RG-GSCs. Scale bar: 100 µm. (B) Quantitative analysis of neurospheres formation efficiency (SFE). ***, p < 0.001, compared with corresponding ev; ###, p < 0.001, compared with corresponding parental cells. (C) Knockdown of PDCD10 increases the mRNA expression of stemness genes in RG-GSCs. The expression of stem cell markers Nestin and KLF4 was detected by RT2-PCR in untreated U87-RG-GSCs, and in shU87-RG-GSCs treated with TMZ (150 µM) for 72 h. *, p < 0.05; ***, p < 0.001, compared with corresponding ev; #, p < 0.05; ###, p < 0.001, compared with evC; +, p < 0.05, compared with corresponding C. (D) Knockdown of PDCD10 enhances the viability of parental U87-RG cells and their GSC variants. U87-RG cells (left) and U87-RG-GSCs (right) received TMZ (150 M) or vehicle DMSO (0.1%) treatment for 72 h. Cell viability was detected after 72 h of treatment. *, p < 0.05; **, p < 0.01; ***, p < 0.001, compared with corresponding ev; #, p < 0.05; ##, p < 0.01, compared with evC; +, p < 0.05, ++, p < 0.01, compared with corresponding parental cells. (E) Knockdown of PDCD10 reduces the mRNA expression of MMR genes (MSH2, MSH6, and PMS2) in U87-RG-GSCs. U87-RG-GSCs received treatment of 150 µM TMZ or vehicle (0.1% DMSO; no treatment). Cells were harvested for PCR detection of MMR genes after 72 h of treatment. Expression of MMR genes in non-treated (Ea) and TMZ-treated U87-RG-GSCs (Eb). *, p < 0.05; **, p < 0.01; ***, p < 0.001, compared with ev.
Fig 2: PDCD10 expression determines the colony formation capacity of GBM cells. ev/shT98g-RG (A) and ev/oxT98g (B) cells received 300 µM of TMZ or vehicle (0.2% DMSO) treatment. Cells were harvested for colony formation assay in a 12-well plate in triplicate after 72 h of TMZ treatment (treatment phase) and at 3 d after TMZ-washing-out and culturing in drug-free media (post-treatment phase). The number of colonies was quantified after staining with 0.5% crystal violet using the ImageJ software (version 1.54j). Representative images of colony formation in ev/shT98g-RG and ev/oxT98g are shown in (Aa) and (Ba), respectively. Quantitative analysis of the colony numbers is presented in (Ab) and (Bb) for ev/shT98g-RG and ev/oxT98g cells, respectively. ***, p < 0.001, compared with ev; ##, p < 0.01 and ###, p < 0.001, compared with corresponding C; +++, p < 0.001, compared with corresponding group in the treatment phase.
Fig 3: DNA replication in response to TMZ treatment is dependent on PDCD10 expression. DNA replication was detected by EdU incorporation followed by FACS at 72 h of TMZ treatment (treatment phase) and at 3 d after TMZ-washing-out and -culturing in drug-washout media (post-treatment phase). ev/shT98g-RG and ev/oxT98g cells received 500 and 300 µM TMZ, respectively. (A,C) Histograms of EdU-positive (EdU+) and -negative (EdU−) cell populations in ev/shT98g-RG and ev/oxT98g cells, respectively. (B,D) Bar graphs of EdU+/− populations based on the corresponding histograms in (A,C). Knockdown of PDCD10 leads to an increase in DNA replication in both the treatment and post-treatment phases of T98g-RG cells, whereas overexpression of PDCD10 suppresses DNA replication in response to TMZ treatment. The data are representative of at least three independent experiments.
Fig 4: Knockdown of PDCD10 confers TMZ-resistance on GBM cells. (A) Confirmation of PDCD10 knockdown in lentiviral transduced U87 and T98g cells by RT2-PCR (a), western blot (b), and semi-quantitation of the blots (c). ev and sh: empty vector- and PDCD10 shRNA-transduced cells, respectively. IOD: integrated optical density. *, p < 0.05; **, p < 0.01; ***, p < 0.001, compared with ev. (B) Knockdown of PDCD10 in GBM cells leads to a resistance to TMZ-induced cell death. U87 and T98g cells received the treatment with 150 µM (a) and 300 µM (b) of TMZ, respectively, for 72 h. Thereafter, TMZ was washed-out. Remaining viable cells were cultured in the TMZ-free medium for 3 d, which is defined as the post-treatment phase. Control cells (C) were treated with vehicle DMSO (0.1% and 0.2% for U87 and T98g, respectively). MTT assay was performed to determine the viability of cells at 72 h after TMZ treatment (treatment phase) and 3 d after washing-out of TMZ (post-treatment phase). *, p < 0.05; **, p < 0.01; ***, p < 0.001, compared with ev; ##, p < 0.01; ###, p < 0.0001, compared with evC in the same phase; +++, p < 0.001, compared with corresponding group in treatment phase.
Fig 5: Overexpression of PDCD10 sensitizes GBM cells to TMZ treatment. (A) Confirmation of overexpression of PDCD10 in lentiviral transduced U87 and T98g cells by RT2-PCR (a) and western blot (b) and semi-quantitation of the blots (c). Western blotting with anti-V5 antibody distinguishes between the expression of transgenic C-terminal V5-tagged PDCD10 protein and endogenous protein. ev and ox: empty vector-transduced and PDCD10-overexpressing cells, respectively. IOD: integrated optical density. *, p < 0.05; **, p < 0.01; ***, p < 0.001, compared with ev. (B) Overexpression of PDCD10 significantly reduces cell viability in a concentration-dependent manner after 72 h of TMZ treatment in both oxU87 (a) and oxT98g (b) cells. Control cells (C) were treated with vehicle DMSO (0.1% and 0.2% for U87 and T98g, respectively). *, p < 0.05; **, p < 0.01; ***, p < 0.001, compared with corresponding ev groups. (C) Overexpression of PDCD10 sensitizes GBM cells to TMZ treatment 72 h after TMZ treatment (treatment phase) and 3 d after washing-out TMZ (post-treatment phase). ev/oxU87 and ev/oxT98g cells received the treatment with 150 µM (a) and 300 µM (b) of TMZ for 72 h, respectively. Thereafter, TMZ-containing medium and dead cells were washed-out and the viable cells were further cultured in drug-free medium for 3 d followed by MTT assay. Control cells (C) were treated with vehicle DMSO (0.1% and 0.2% for U87 and T98g, respectively). *, p < 0.05; **, p < 0.01; ***, p < 0.001, compared with corresponding ev groups; +++, p < 0.001, compared with corresponding evC in the treatment phase; #, p < 0.05, ###, p < 0.001, compared with corresponding evC in the same phase.
Supplier Page from OriGene Technologies for PDCD10 Human shRNA Plasmid Kit (Locus ID 11235)